$ADAG

Adagene Inc.

Adagene is a clinical-stage biotechnology company that uses computational biology to discover and develop antibody-based cancer immunotherapies. Its Dynamic Precision Library platform supports three technologies: NEObody for antibody discovery, SAFEbody for antibodies designed to activate mainly in the tumor microenvironment, and POWERbody for engineered antibodies including T-cell engagers. Its lead candidate, ADG126, is an anti-CTLA-4 SAFEbody in clinical development, initially focused on metastatic microsatellite-stable colorectal cancer. The pipeline also includes other clinical, preclinical and discovery-stage candidates. Adagene works with biotechnology and pharmaceutical companies on technology licensing and product-candidate out-licensing, and retains potential participation in product sales through royalties. It also collaborates on clinical development. The company is incorporated in the Cayman Islands and operates through subsidiaries, with research and development activities in China, the United States, Australia and Singapore. Its corporate headquarters is in Suzhou, Jiangsu Province, China.

0
2
0

No SEC Form 4 filings for $ADAG in the last 30 days.

See all $ADAG insider activity →

Adagene completes enrollment in phase 2 trial of muzastotug

Adagene Inc. (ADAG) completed enrollment in a Phase 2 trial of muzastotug, an anti-CTLA-4 antibody therapy, combined with Merck’s KEYTRUDA for late-line colorectal cancer. The trial enrolled 60 patients, with results expected in early 2027. The FDA confirmed Phase 3 trial design elements, and Sanofi invested in the trial. Muzastotug has FDA Fast Track designation.

Chardan Capital maintains Buy rating on Adagene, $9 price target

Chardan Capital kept a Buy rating and $9 price target on Adagene, implying 248.8% upside from the Oct 27 close. The firm cited Adagene's strong immunotherapy pipeline, including ADG126 in clinical trials, and its advanced antibody design technologies.

ADAG sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 2 news stories mentioning ADAG (Adagene Inc.). Coverage has been balanced: 0 bullish, 2 neutral, and 0 bearish.

Recent ADAG coverage spans financial news, insider activity and technology.

What's driving ADAG

  • Early-stage trial initiation is a modest positive catalyst for ADAG, but it does not yet provide efficacy or safety readouts.

    tradingview.com · Nov 17, 2026

  • The enrollment completion is a positive milestone that may lift the stock ahead of upcoming data, but the impact is contingent on Phase 3 outcomes.

    investing.com · Nov 9, 2026

  • Chardan Capital kept a Buy rating and $9 price target on Adagene, implying 248.8% upside from the Oct 27 close. The firm cited Adagene's strong immunotherapy pipeline, including ADG126 in clinical trials, and its advanced antibody design technologies.

    tradingview.com · Oct 28, 2026

  • The trial start introduces a new catalyst that could lift ADAG if early data are positive.

    investing.com · Oct 28, 2026

  • Positive early data may boost investor sentiment toward ADAG.

    rttnews.com · Oct 26, 2026

AlphAI scores every news story that mentions ADAG with an AI model for sentiment and relevance, and aggregates insider trades from Adagene Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $ADAG

Score
$ADAGLowAI 8/10

Adagene completes enrollment in phase 2 trial of muzastotug

Adagene Inc. (ADAG) completed enrollment in a Phase 2 trial of muzastotug, an anti-CTLA-4 antibody therapy, combined with Merck’s KEYTRUDA for late-line colorectal cancer. The trial enrolled 60 patients, with results expected in early 2027. The FDA confirmed Phase 3 trial design elements, and Sanofi invested in the trial. Muzastotug has FDA Fast Track designation.

Adagene Eyes Phase II Data for Masked CTLA-4 Therapy in MSS Colorectal Cancer

Adagene (NASDAQ:ADAG) anticipates Phase II data for its CTLA-4 therapy in MSS colorectal cancer, aiming to replicate Phase Ib response rates of 17-25%. The company plans FDA meetings post-Phase II and potential Phase III trials. Adagene also has a neoadjuvant study in Singapore, with results expected in 2027. It collaborates with Incyte on a combination therapy and has a cash runway into 2028.

Related tickers